Buscar resultados de ensayos clínicos
Inflammatory Breast Cancer - 25 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Case-Control Study of Inflammatory Breast Cancer in North Africa Condición: Inflammatory Breast Cancer Fecha: 2008-11-18 |
Recruiting |
Nombre del estudio: Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer Condición: Inflammatory Breast Cancer Fecha: 2011-05-25 Intervenciones:
|
Completed |
Nombre del estudio: Establishing an Inflammatory Breast Cancer Registry Condición: Inflammatory Breast Cancer Fecha: 2006-06-19 |
Completed |
Nombre del estudio: Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia Condición: Inflammatory Breast Cancer Fecha: 2006-06-23 |
Recruiting |
Nombre del estudio: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Condición: Inflammatory Breast Cancer (IBC) Fecha: 2016-08-09 Intervenciones:
|
Completed |
Nombre del estudio: Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Condición: Inflammatory Breast Cancer Fecha: 2014-12-14 Intervenciones:
|
Recruiting |
Nombre del estudio: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Condición:
|
Recruiting |
Nombre del estudio: Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy Condición: Inflammatory Breast Carcinoma Fecha: 2013-06-25 Intervenciones:
|
Recruiting |
Nombre del estudio: A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy Condición:
Fecha: 2016-11-21 Intervenciones: Drug: Pembrolizumab Pembrolizumab 200 mg administered on day 1 of each 3-week cycle as approximately 30 |
Not yet recruiting |
Nombre del estudio: Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Condición:
Fecha: 2016-09-02 Intervenciones: |